Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Innovation: Clinical trials
Abbreviations
177Lu-PSMA-617- Radioligand therapy targeting prostate
specific membrane antigen (PSMA)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT03511664 VISION (PSMA-617-01)
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 3
831
Radiographic Progression Free Survival
Overall Survival
177Lu-PSMA-617 plus BS/BSC
BS/BSC alone
Adult patients with PSMA-positive Metastatic Castration-resistant Prostate Cancer
(mCRPC)
Primary Analysis: Mar-2021 (Actual)
Final Analysis: Q4-2022
Morris et al. Presented at ASCO (6-Jun-2021)
Manuscript e-publication expected Jun-2021
94 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation